- Home
- LU vs EWTX Comparison
LU vs EWTX Comparison
Compare LU & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- EWTX
- Stock Information
- Founded
- LU 2005
- EWTX 2017
- Country
- LU China
- EWTX United States
- Employees
- LU N/A
- EWTX N/A
- Industry
- LU Finance: Consumer Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- LU Finance
- EWTX Health Care
- Exchange
- LU Nasdaq
- EWTX Nasdaq
- Market Cap
- LU 2.8B
- EWTX 2.3B
- IPO Year
- LU 2020
- EWTX 2021
- Fundamental
- Price
- LU $2.97
- EWTX $22.00
- Analyst Decision
- LU Hold
- EWTX Buy
- Analyst Count
- LU 2
- EWTX 8
- Target Price
- LU $2.98
- EWTX $45.38
- AVG Volume (30 Days)
- LU 3.9M
- EWTX 1.5M
- Earning Date
- LU 04-21-2025
- EWTX 03-03-2025
- Dividend Yield
- LU 79.13%
- EWTX N/A
- EPS Growth
- LU N/A
- EWTX N/A
- EPS
- LU N/A
- EWTX N/A
- Revenue
- LU $4,671,260,668.00
- EWTX N/A
- Revenue This Year
- LU N/A
- EWTX N/A
- Revenue Next Year
- LU $1.48
- EWTX N/A
- P/E Ratio
- LU N/A
- EWTX N/A
- Revenue Growth
- LU N/A
- EWTX N/A
- 52 Week Low
- LU $2.00
- EWTX $14.90
- 52 Week High
- LU $4.94
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- LU 47.91
- EWTX 34.61
- Support Level
- LU $2.93
- EWTX $21.58
- Resistance Level
- LU $3.10
- EWTX $25.36
- Average True Range (ATR)
- LU 0.13
- EWTX 2.11
- MACD
- LU -0.04
- EWTX -0.27
- Stochastic Oscillator
- LU 23.19
- EWTX 6.94
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.